Legend Biotech
LEGN
200 hedge funds and large institutions have $5.78B invested in Legend Biotech in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 71 increasing their positions, 70 reducing their positions, and 15 closing their positions.
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
3% more funds holding
Funds holding: 194 → 200 (+6)
1% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 70
0.52% more ownership
Funds ownership: 25.54% → 26.05% (+0.52%)
1% less capital invested
Capital invested by funds: $5.81B → $5.78B (-$37.9M)
8% less call options, than puts
Call options by funds: $16.9M | Put options by funds: $18.4M
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$59.8M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$48.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$46M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$31.4M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$28.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$79.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$34.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$23.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.8M |
| 5 |
Millennium Management
New York
|
-$17.1M |
LEGN Hedge Fund Activity: Q3 2023 in Review
200 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q3 2023, worth a combined $5.78B — down 0.65% from $5.81B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LEGN positions and 15 closed out — a net gain of 8 holders — while 71 added to existing stakes and 70 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $59.8M. The largest seller was Fidelity Investments, cutting an estimated $79.2M.
- 200 institutional investors held Legend Biotech (LEGN) as of Q3 2023, up from 194 in Q2 2023.
- Funds reported $5.78B of Legend Biotech stock for Q3 2023, down 0.65% quarter-over-quarter.
- 23 funds opened new Legend Biotech positions in Q3 2023 and 15 closed out, a net change of +8 holders.
- The largest Legend Biotech buyer in Q3 2023 was Adage Capital Partners, an estimated $59.8M added.
- The largest Legend Biotech seller in Q3 2023 was Fidelity Investments, an estimated $79.2M sold.
Based on aggregated 13F filings for Q3 2023.